Marion Subklewe

2.1k total citations
24 papers, 257 citations indexed

About

Marion Subklewe is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Marion Subklewe has authored 24 papers receiving a total of 257 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Marion Subklewe's work include CAR-T cell therapy research (22 papers), Biosimilars and Bioanalytical Methods (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Marion Subklewe is often cited by papers focused on CAR-T cell therapy research (22 papers), Biosimilars and Bioanalytical Methods (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Marion Subklewe collaborates with scholars based in Germany, United States and Spain. Marion Subklewe's co-authors include Kai Rejeski, Veit Bücklein, Nirali N. Shah, Michael von Bergwelt‐Baildon, Michael D. Jain, Miguel‐Angel Perales, Viktoria Blumenberg, Christian Schmidt, Pankit Vachhani and Sophia K. Khaldoyanidi and has published in prestigious journals such as Blood, International Journal of Cancer and Haematologica.

In The Last Decade

Marion Subklewe

18 papers receiving 256 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marion Subklewe Germany 10 212 71 66 65 40 24 257
Sandra B. Horowitz United States 9 227 1.1× 77 1.1× 78 1.2× 65 1.0× 40 1.0× 14 305
Ana Alarcón Tomás United States 8 177 0.8× 50 0.7× 33 0.5× 42 0.6× 38 0.9× 22 233
Bryan Do United States 6 187 0.9× 49 0.7× 32 0.5× 53 0.8× 37 0.9× 7 288
Ceri Jones United Kingdom 6 128 0.6× 65 0.9× 24 0.4× 30 0.5× 33 0.8× 17 213
Patricia Steinert United States 6 178 0.8× 48 0.7× 87 1.3× 32 0.5× 43 1.1× 19 250
Yuehui Lin China 8 250 1.2× 53 0.7× 40 0.6× 57 0.9× 61 1.5× 27 292
Daniella Cook United States 7 167 0.8× 64 0.9× 37 0.6× 30 0.5× 40 1.0× 14 185
Zhuojun Ling China 9 310 1.5× 64 0.9× 29 0.4× 78 1.2× 100 2.5× 20 332
Matteo Doglio Italy 8 150 0.7× 50 0.7× 22 0.3× 116 1.8× 30 0.8× 19 245
Miriam Sánchez‐Escamilla Spain 5 193 0.9× 56 0.8× 36 0.5× 66 1.0× 72 1.8× 13 239

Countries citing papers authored by Marion Subklewe

Since Specialization
Citations

This map shows the geographic impact of Marion Subklewe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marion Subklewe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marion Subklewe more than expected).

Fields of papers citing papers by Marion Subklewe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marion Subklewe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marion Subklewe. The network helps show where Marion Subklewe may publish in the future.

Co-authorship network of co-authors of Marion Subklewe

This figure shows the co-authorship network connecting the top 25 collaborators of Marion Subklewe. A scholar is included among the top collaborators of Marion Subklewe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marion Subklewe. Marion Subklewe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schreiber, Yannick, et al.. (2024). Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia. Clinical and Experimental Medicine. 24(1). 155–155.
2.
Díaz, Juan Manuel Mancilla, Saurabh Dahiya, Maeve O’Reilly, et al.. (2024). Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies. Blood. 144(Supplement 1). 7239–7239.
3.
Rejeski, Kai, Michael D. Jain, Nirali N. Shah, Miguel‐Angel Perales, & Marion Subklewe. (2024). Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. The Lancet Haematology. 11(6). e459–e470. 29 indexed citations
4.
Sureda, Anna, Pieternella J. Lugtenburg, Marie José Kersten, et al.. (2023). Cellular therapy in lymphoma. Hematological Oncology. 42(6). e3200–e3200. 3 indexed citations
5.
6.
Ravandi, Farhad, Jacqueline Cloos, Francesco Buccisano, et al.. (2023). Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel. American Journal of Hematology. 98(12). 1847–1855. 10 indexed citations
7.
Stock, Sophia, et al.. (2023). Mechanisms and strategies for safe chimeric antigen receptor T‐cell activity control. International Journal of Cancer. 153(10). 1706–1725. 16 indexed citations
8.
Westin, Jason R., et al.. (2023). The race is on: bispecifics vs CAR T cells in B-cell lymphoma. Blood Advances. 7(19). 5713–5716. 11 indexed citations
9.
Marcinek, Anetta, Tobias Straub, Gerulf Hänel, et al.. (2023). Beyond Mitigating Immune-Related Adverse Events: Glucocorticoids Ameliorate Bispecific Antibody-Mediated T-Cell Exhaustion I n Vitro. Blood. 142(Supplement 1). 5389–5389. 1 indexed citations
10.
Rejeski, Kai, Doris K. Hansen, Yucai Wang, et al.. (2023). Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality. Blood. 142(Supplement 1). 359–359. 1 indexed citations
11.
Schubert, Maria‐Luisa, Wolfgang Bethge, Francis Ayuk, et al.. (2023). Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study. Blood Advances. 7(20). 6191–6195. 9 indexed citations
12.
Winkelmann, Michael, Viktoria Blumenberg, Kai Rejeski, et al.. (2023). Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy. Journal for ImmunoTherapy of Cancer. 11(10). e006659–e006659.
13.
Winkelmann, Michael, Viktoria Blumenberg, Kai Rejeski, et al.. (2023). Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria. Cancer Imaging. 23(1). 44–44. 1 indexed citations
14.
Vick, Binje, Karsten Spiekermann, Maja Rothenberg‐Thurley, et al.. (2022). WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice. Blood. 141(8). 955–960. 1 indexed citations
15.
Santos, David M. Cordas dos, Kai Rejeski, Michael Winkelmann, et al.. (2022). Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies. Haematologica. 107(9). 2096–2107. 24 indexed citations
16.
Tiedt, Steffen, Anita Schmitt, Viktoria Blumenberg, et al.. (2022). Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment. Blood Advances. 6(10). 3022–3026. 28 indexed citations
17.
Rejeski, Kai, Andreas Burchert, Gloria Iacoboni, et al.. (2022). Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Advances. 6(16). 4719–4725. 36 indexed citations
18.
Iacoboni, Gloria, Kai Rejeski, Annalisa Chiappella, et al.. (2021). Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. Blood. 138(Supplement 1). 2827–2827. 7 indexed citations
19.
Rejeski, Kai, Carolina Berger, Semjon Willier, et al.. (2020). Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies. Blood. 136(Supplement 1). 41–42. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandra B. Horowitz Breakdown of academic impact, for papers by Ana Alarcón Tomás Breakdown of academic impact, for papers by Bryan Do Breakdown of academic impact, for papers by Ceri Jones Breakdown of academic impact, for papers by Patricia Steinert Breakdown of academic impact, for papers by Yuehui Lin Breakdown of academic impact, for papers by Daniella Cook Breakdown of academic impact, for papers by Zhuojun Ling Breakdown of academic impact, for papers by Matteo Doglio Breakdown of academic impact, for papers by Miriam Sánchez‐Escamilla
Rankless by CCL
2026